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ABSTRACT
Griscelli syndrome (GS) is a rare autosomal recessive disorder resulting in pigmentary dilution of the skin and hair with variable 
phenotypes depending upon the underlying genetic mutation. Mutations in 3 distinct genes MYO5A, RAB27A, MLPH are responsible 
for 3 subtypes (GS1, GS2, and GS3) of GS respectively. Griscelli syndrome type 2 (GS-2) is a rare autosomal recessive disease. It 
commonly presents with hemophagocytic lymphohistiocytosis (HLH) and recurrent infections due to immunodeficiency. We describe 
a 3-year-old female with pyrexia, silvery hair, lymphadenopathy, hepatosplenomegaly, and hemophagocytosis. We found a novel 
compound heterozygous mutation in the RAB 27A gene. She succumbed despite being on dexamethasone and septran prophylaxis. 
This case spreads awareness about this rare potentially fatal disease, as a high index of suspicion is required for prompt diagnosis and 
treatment. Early bone marrow transplant is the only curative treatment for GS-2. 
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Griscelli syndrome (GS), a rare autosomal recessive disorder is characterized by partial albinism, along with immunologic abnormalities or severe neurological 
impairment or both [1]. Only 14 cases have been reported from 
India, the last reported in 2017 [2]. Mutation in 3 distinct genes 
MYO5A, RAB27A, MLPH is responsible for 3 subtypes (GS1, 
GS2, and GS3) of GS respectively [1-4]. Most of the patients with 
GS-2 display the hemophagocytic syndrome and have mutations 
in RAB27A gene [2]. A high index of suspicion is required for the 
prompt diagnosis and treatment of this potentially fatal disease 
and prevent complications. Chemotherapy followed by bone 
marrow transplant is the only curative treatment. 
CASE REPORT
A 3-year-old girl born of non-consanguineous parentage 
presented with a history of high-grade fever without chills and 
rigors since 2.5 months. She had a history of painless right-sided 
neck swelling, around 3x 4 cm in size a few months back which 
lasted for 15 days until she underwent aright cervical lymph node 
biopsy. She was admitted to a hospital 2 months back for these 
complaints.
On examination, she had pallor. Her abdominal examination 
revealed splenomegaly of 3 cm and the liver was palpable 2 
cm below the costal margin. Her complete blood count showed 
pancytopenia with hemoglobin of 6.0 gm/dl, white blood cells 3.2 
x109/L (L - 62%, P - 30%) and platelet count was 90,000/mm3. 
Her lactate dehydrogenase (LDH) was significantly elevated 
at 1948 U/L. Chest X-ray showed left-sided infiltrates. Her 
lymph node biopsy showed reactive lymphocytes. It did 
not reveal any granulomas. There was no increase in blasts, 
immunohistochemistry (IHC) for a cluster of differentiation 
(CD) 20 and CD 30 was negative. Ziehl Neelsen and Gomori 
Methenamine-Silver (GMS) were negative. Bone marrow 
aspiration and biopsy revealed a cellular marrow with increased 
macrophages and hemophagocytosis. There was no increase in 
blasts. Her parents refused chemotherapy, so, she was started 
on anti-tubercular therapy (ATT), since tuberculosis was a close 
differential. They stopped ATT after 5 days in view of persistent 
fever and mistrust. 
At presentation, she was afebrile since 4 days. She had lost 3 
kg weight in the last 2 months. Her father denied any history of 
bleeding manifestations, bony pains and night sweats. She had a 
very characteristic silvery hair of the scalp, body, eyelashes and 
eyebrows (Fig. 1). The skin and iris had normal pigmentation. 
She had pallor. Abdominal examination revealed a just palpable 
spleen and hepatomegaly 3 cm. Other systems were normal. 
Her investigations at our hospital showed a hemoglobin of 
10 gm/dl, WBC count of 7.18 x109 /L and platelet count 313,000/
mm3. Peripheral smear showed microcytic hypochromic anemia. 
Polymorphs lacked the hallmark giant granules of Chediak 
Higashi syndrome. LDH was within normal limits at 556 U/L. 
Serum ferritin was raised 252.78 ng/ml. Serum Triglyceride was 
normal at 184.0 mg/dl.
Dhakate & Rajput  Griscelli syndrome type 2
Vol 5 | Issue 6 | Nov - Dec 2019 Indian J Case Reports    513
She was advised admission and chemotherapy for further 
management, however father refused admission despite 
explaining the life threatening nature of the disease. She was 
started on Dexamethasone 10 mg once a day and Septran 
prophylaxis (single strength twice a day every Monday and 
Friday) for 1 month. 
Bone marrow aspiration slides were reviewed later which 
showed profound hemophagocytic activity (Fig. 2).The genetic 
test for familial hemophagocytic lymphohistiocytosis (HLH) was 
positive for a compound heterozygous mutation in the RAB 27A 
gene. A heterozygous c.550C>T nonsense variation in exon 6 of the 
RAB27A gene that results in a stop codon was detected. Another, 
heterozygous 5’ splice site variation in intron 3 of the RAB27A 
gene that affects the invariant GT donor splice-site downstream 
of exon 3 (c.239+1G>T) was detected (Fig. 3). This confirmed 
Griscelli syndrome type 2. As per telephonic conversation, she 
was afebrile for 3 weeks, but became acutely sick with sudden 
enlargement of the cervical lymphnodes and succumbed.
DISCUSSION
Claude Griscelli first described two unrelated patients with partial 
albinism, frequent pyogenic infections and acute episodes of 
fever, neutropenia and thrombocytopenia in 1978 [1]. GS is a rare 
autosomal recessive disorder caused by mutations in MYO5A 
(Myosin VA), RAB27A (Ras related protein Rab-27A) and 
MLPH (melanophilin) genes which are responsible for the varied 
manifestations of type 1, 2, and 3 respectively [2-4]. GS 1 usually 
manifests with primary dysfunction of the central nervous system 
without immunological involvement. However, Yair Anikster 
conjectured that GS 1 with primary neurological involvement 
caused by mutations in MYO5Ais synonymous with Elejalde 
syndrome [5]. GS 2 is characterized by HLH and recurrent 
infections while GS 3 manifests with only partial albinism. GS 2 is 
often fatal; therefore, early recognition of patients with GS-2 and 
prompt intervention with bone marrow transplant is critical [6].
GS2 is a rare primary immunodeficiency disease with the 
characteristic silvery gray hair of the scalp and body. Microscopic 
examination of hair reveals uneven clusters of aggregated melanin 
pigment, accumulated mainly in the medullary area of the shaft 
[7]. Skin biopsy shows increased deposition of melanosomes 
in the melanocytes contrasting with poorly pigmented adjacent 
keratinocytes. The immunodeficiency seen in GS2 is due to 
impairment of T-cell and natural killer cytotoxic activity, resulting 
in susceptibility to repeated infections. Bone marrow aspiration 
and biopsy show HLH in most of the cases of GS2. 
Our patient presented with a constellation of fever, silvery 
gray hair, cytopenias, splenomegaly and hemophagocytosis. The 
peripheral smear did not reveal the characteristic coarse granules 
in the neutrophils excluding the possibility of Chedaik-Higashi 
syndrome. A genetic test for Familial HLH demonstrated a novel 
compound heterozygous mutation in RAB27A gene. A heterozygous 
nonsense variation in exon 6 of the RAB27A gene that results in a 
stop codon and premature truncation of the protein at codon 184 
(p.Arg184) was detected. This signifies C550T leading to R184X 
mutation. Another, heterozygous 5’ splice site variation in intron 3 
of the RAB27A genethat affects the invariant GT donor splice-site 
downstream of exon 3 (c.239+1G>T) was detected. 
These genetic mutations have been independently reported as 
homozygous mutations in case reports. This is the first case report 
of such a compound heterozygous mutation from India leading 
to GS. A homozygous C550T leading to R184X mutation (X is a 
stop mutation) in RAB27A gene was identified in two case reports 
from India [8,9]. In another case report from India homozygous 
splice site mutation in c239+1 G-T in intron 3 was reported in a 
1-year old child presenting with seizures and neurodevelopmental 
regression. The parents were heterozygous for the said mutation 
[10,11]. Compound heterozygous mutations have been reported 
Figure 1: Silvery-gray hair of the scalp, eyebrows, and eyelashes in 
the indexed case.
Figure 2: Bone marrow aspiration showing hemophagocytosis of 
hematopoietic cells suggestive of HLH.
Figure 3: The genetic test for familial HLH.
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earlier from a Swedish family. Table 1 gives a list of cases 
reported from India with their salient clinical features. 
CONCLUSION
Griscelli syndrome subtype 2 is a rare primary immunodeficiency 
disease with the characteristic silvery gray hair of the scalp 
and body. Griscelli syndrome is a spot diagnosis due to the 
characteristic silvery hair over the entire body. It is a fatal disorder 
if not recognized and treated timely. The only curative treatment 
is a stem cell transplant. 
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Mutation Outcome at the 
time of case 
report
1 20 mMale Subtype 2 no + + +
Not 
documented Alive
2 12 mFemale Subtype 2 yes + + +
Homozygous 
RAB 27 A Died
3 13 dayMale Subtype 2 No + No No
Homozygous 
RAB 27 A Alive
4 22 mMale Subtype 2 Yes + + +
Not 
documented Died
5 30 mMale Subtype 2 no + + +
Homozygous 
RAB 27 A Alive
6 4 yrmale Subtype 2 No + + +
Not 
documented Alive
7 5 yrMale Subtype 2 No + + +
Homozygous 
RAB 27 A Alive
8 9 yrmale Subtype 3 No + No No
Not 
documented Alive
9 11 mmale Subtype 2 Yes + No +
Not 
documented Alive
10 1 yearmale Subtype 2 no + + +
Not 
documented Alive
11 2.5 year Subtype 2 no + + +
Homozygous 
RAB 27 A Alive
12 7 year female Subtype 2 no + No No
Not 
documented Alive
13 1 year male Subtype 2 no + + +
Not 
documented Alive
Table1: Original: Cases of Griscelli syndrome from India with their salient clinical features.
